Aspirin News and Research RSS Feed - Aspirin News and Research

Aspirin also known as acetylsalicylic acid is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet, or "anti-clotting", effect and is used in long-term, low doses to prevent heart attacks, strokes and blood clot formation in people at high risk for developing blood clots. It has also been established that low doses of aspirin may be given immediately after a heart attack to reduce the risk of another heart attack or of the death of cardiac tissue.
International Aspirin Foundation seeks applicants for Senior Science Award 2016

International Aspirin Foundation seeks applicants for Senior Science Award 2016

The International Aspirin Foundation, founded in 1974, is seeking applicants for the Senior Science Award 2016. This is open to scientists who can demonstrate a track record of valuable, significant medical scientific research (basic, translational or clinical), contributing to the scientific knowledge of aspirin/acetylsalicylic acid. [More]
U of M's 'Ask About Aspirin' initiative aims to reduce incidence of first heart attack or stroke

U of M's 'Ask About Aspirin' initiative aims to reduce incidence of first heart attack or stroke

Cardiovascular diseases are the leading causes of death and disability in the United States, accounting for nearly one-third of all deaths. The diseases also create an immense national health economic burden. [More]
Using painkillers during pregnancy may harm fertility of daughters

Using painkillers during pregnancy may harm fertility of daughters

Using painkillers in pregnancy may reduce fertility in subsequent generations, research suggests. Tests in rats found that when a mother was given painkillers during pregnancy, her female offspring had fewer eggs, smaller ovaries and smaller litters of babies than those not exposed to the drugs. [More]
Cardiovascular considerations crucial for CML TKI patients

Cardiovascular considerations crucial for CML TKI patients

A review of BCR–ABL1 tyrosine kinase inhibitors highlights the need to consider cardiovascular adverse event risk profiles when prescribing for patients with chronic myeloid leukaemia. [More]
Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Allergan plc announced today the publication of the positive results of the Phase III trials of VIBERZITM C IV (eluxadoline) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in the January 21 issue of The New England Journal of Medicine. [More]
Study outlines new model to help predict age-related response to hepatitis B vaccine

Study outlines new model to help predict age-related response to hepatitis B vaccine

Physicians have known for years that patients respond differently to vaccines as they age. There may soon be a new way to predict and enhance the effectiveness of vaccinations, in particular the hepatitis B vaccine. [More]
New Georgia Tech research center launched to manufacture living cells for cell-based therapies

New Georgia Tech research center launched to manufacture living cells for cell-based therapies

A $15.7 million grant from the Atlanta-based Marcus Foundation has helped launch a new Georgia Institute of Technology research center that will develop processes and techniques for ensuring the consistent, low-cost, large-scale manufacture of high-quality living cells used in cell-based therapies. [More]
Specialized oral nutrition supplement associated with 50% lower death rate in older patients

Specialized oral nutrition supplement associated with 50% lower death rate in older patients

Results from a new clinical trial show that a specialized oral nutrition supplement was associated with a 50 percent lower death rate in older malnourished patients with a heart or lung disease 90 days following hospitalization. [More]
TSRI scientists receive $2.1 million NIH grant to create new library of drug candidates

TSRI scientists receive $2.1 million NIH grant to create new library of drug candidates

Scientists at The Scripps Research Institute have received a grant of more than $2.1 million from the National Institutes of Health's National Institute of General Medical Sciences to create and screen a new library of drug candidates. [More]
FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

New Haven Pharmaceuticals, Inc. today announced the availability by prescription of DURLAZA, the first and only 24-hour, extended-release aspirin capsules (162.5mg) approved by the U.S. Food and Drug Administration (FDA) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack) in high-risk cardiovascular patients. [More]
Statins could be effective against metastatic small cell lung cancer

Statins could be effective against metastatic small cell lung cancer

In a recent study, researchers at Cancer Treatment Centers of America at Western Regional Medical Center (Western), in collaboration with international colleagues, found that statins could be an effective therapeutic against metastatic small cell lung cancer (SCLC). [More]
Commonly used diabetes drug may have potential to prevent, treat preeclampsia

Commonly used diabetes drug may have potential to prevent, treat preeclampsia

An article published today in the American Journal of Obstetrics and Gynecology reports that a commonly-used drug for the treatment of diabetes, metformin, may have the potential to prevent and treat preeclampsia. Metformin has long been used to treat diabetes in both non-pregnant and pregnant patients, and is considered safe during pregnancy. [More]
New research suggests use of low-dose aspirin to prevent preeclampsia

New research suggests use of low-dose aspirin to prevent preeclampsia

To prevent preeclampsia, new research suggests that low-dose aspirin should be given prophylactically to all women at high risk (those with diabetes or chronic hypertension) and any woman with two or more moderate risk factors (including obesity, multiple gestation and advanced maternal age). [More]
Immigrant couples at lower risk of having preterm birth than Canadian-born couples

Immigrant couples at lower risk of having preterm birth than Canadian-born couples

Couples who immigrate to Canada are generally at lower risk of having a preterm birth than Canadian-born couples, new research has found. [More]
Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced a collaboration agreement with Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company. [More]
Aspirin does not improve survival among breast cancer patients with aggressive disease

Aspirin does not improve survival among breast cancer patients with aggressive disease

Whether aspirin may help prevent or reduce the risk of breast cancer remains a hotly debated research question. While past studies have indicated a potential benefit, most recently in hormone receptor-positive breast cancers, one new study from Penn Medicine suggests otherwise. [More]
RTFCCR grant supports ASCOLT study that evaluates effectiveness of Aspirin in colorectal cancer patients

RTFCCR grant supports ASCOLT study that evaluates effectiveness of Aspirin in colorectal cancer patients

Rising Tide Foundation for Clinical Cancer Research, an international private foundation based in Switzerland, has awarded a US $800,000 grant to be released over two years for the ASCOLT study conducted by Dr John Chia, Senior Consultant Medical Oncologist at the Division of Medical Oncology, National Cancer Centre Singapore. [More]
XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the results from their real-world study XALIA showing that, in people with deep vein thrombosis (DVT), the rates of major bleeding and recurrent blood clots for XARELTO (rivaroxaban) in routine clinical practice were generally consistent with those observed in Phase 3 research. [More]
Identifying new mechanism for aspirin in cancer prevention

Identifying new mechanism for aspirin in cancer prevention

Aspirin has been shown to decrease the risk of colorectal cancer and possibly other cancers. However, the risk of side effects, including in some cases severe gastrointestinal bleeding, makes it necessary to better understand the mechanisms by which aspirin acts at low doses before recommending it more generally as a preventative, says Cornelia Ulrich, PhD, Senior Director of Population Sciences at Huntsman Cancer Institute in Salt Lake City. [More]
New data validates use of ActiveCare DVT prophylaxis compression system following total joint replacement surgery

New data validates use of ActiveCare DVT prophylaxis compression system following total joint replacement surgery

Medical Compression Systems, Inc. (MCS), today announced new data further validating the use of the ActiveCare DVT prophylaxis compression system following total joint replacement procedures. [More]
Advertisement
Advertisement